Joshua Walter Kranrod

Mr. Joshua Walter Kranrod

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NMNatsumi Miyazaki
Natsumi Miyazaki
RSReika Shiratori
Reika Shiratori
TOTaichi Oshima
Taichi Oshima
ZZZhiheng Zhang
Zhiheng Zhang
RVRobert Valencia
Robert Valencia
SAShigeki Aoki
Shigeki Aoki

28 June 2024 in The FASEB Journal
Verified
Journal Article
Open access
RVRobert Valencia
Robert Valencia
JKJoshua Walter Kranrod
Joshua Walter Kranrod
LFLiye Fang
Liye Fang
ASAmro M. Soliman
Amro M. Soliman
BABrandon Azer
Brandon Azer
JSJohn M Seubert
John M Seubert
12,13‐dihydroxy‐9z‐octadecenoic acid (12,13‐DiHOME) is a linoleic acid diol derived from cytochrome P‐450 (CYP) epoxygenase and epoxide hydrolase (EH) metabolism. 12,13‐DiHOME is associated with inflammation and mitochondrial damage in the innate immune response, but how 12,13‐DiHOME contributes to these effects is unclear. We hypothesized that 12,13‐DiHOME enhances macrophage inflammation through effects on NOD‐like receptor protein 3 (NLRP3) inflammasome activation. To test this hypothesis, we utilized human monocytic THP1 cells differentiated into macrophage‐like cells with phorbol myristate acetate (PMA). 12,13‐DiHOME present during lipopolysaccharide (LPS)‐priming of THP1 macrophages exacerbated nigericin‐induced NLRP3 inflammasome activation. Using high‐resolution respirometry, we observed that priming with LPS+12,13‐DiHOME altered mitochondrial respiratory function. Mitophagy, measured using mito‐Keima, was also modulated by 12,13‐DiHOME present during priming. These mitochondrial effects were associated with increased sensitivity to nigericin‐induced mitochondrial depolarization and reactive oxygen species production in LPS+12,13‐DiHOME‐primed macrophages. Nigericin‐induced mitochondrial damage and NLRP3 inflammasome activation in LPS+12,13‐DiHOME‐primed macrophages were ablated by the mitochondrial calcium uniporter (MCU) inhibitor, Ru265. 12,13‐DiHOME present during LPS‐priming also enhanced nigericin‐induced NLRP3 inflammasome activation in primary murine bone marrow‐derived macrophages. In summary, these data demonstrate a pro‐inflammatory role for 12,13‐DiHOME by enhancing NLRP3 inflammasome activation in macrophages.

1 January 2023 in Hypertension
Verified
Journal Article
Closed access
PDF file
PAPreetinder K. Aujla
Preetinder K. Aujla
MHMei Hu
Mei Hu
BHBridgette Hartley
Bridgette Hartley
JKJoshua Walter Kranrod
Joshua Walter Kranrod
AVAnissa Viveiros
Anissa Viveiros
ZKZamaneh Kassiri
Zamaneh Kassiri
Background: Myocardial hypertrophy and dilation are key features of cardiomyopathies and involve several cellular and molecular events. ADAMs (a disintegrin and metalloproteinases) are membrane-bound proteinases with diverse functions whose role in heart disease remains underexplored. ADAM15 is expressed in the heart and is downregulated in the failing human heart. We investigated the role ADAM15 in pressure overload cardiomyopathy. Methods: We assessed ADAM15 levels in myocardial specimens from patients. Its direct role in pressure overload was investigated by subjecting wildtype and Adam15 -deficient mice to transverse aortic constriction (TAC). Results: ADAM15 levels did not change in patients with concentric hypertrophy, but markedly decreased in eccentric hypertrophy and heart failure. Loss of ADAM15 alone did not cause cardiomyopathy in mice (1 year old). After TAC, Adam15 -/- mice exhibited worsened eccentric hypertrophy and dilation with greater increase in hypertrophy markers (pJNK, pERK1/2; Nppb, Nppa , Myh7 , Acta1 ) compared with wildtype-TAC. Expression of integrin-α7 (but not integrin β1) increased significantly more in Adam15 -/- -TAC hearts, while the interaction of these integrins with basement membrane (laminin), decreased consistent with worsened left ventricle dilation. In vitro, ADAM15 knockdown increased cardiomyocyte hypertrophy in response to mechanical stretch. Adam15 -/- -TAC hearts exhibited increased calcineurin activity and de-phosphorylation of nuclear factor of activated T cells. Calcineurin inhibition (cyclosporin-A) blocked the excess hypertrophy and dilation in Adam15 -/- -TAC mice. Proteome profiling demonstrated the increased abundance of the key proteins linked to worsened DCM in Adam15 -/- -TAC. Conclusion: This is the first report demonstrating that ADAM15 can suppress hypertrophy through regulating the integrin-laminin interaction and the calcineurin pathway.

1 January 2024 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
JKJoshua Walter Kranrod
Joshua Walter Kranrod
ADAhmed Darwesh
Ahmed Darwesh
WFWesam Farag
Wesam Farag
AHAndy Huang
Andy Huang
LFLiye Fang
Liye Fang
JSJohn M Seubert
John M Seubert
Mounting evidence suggests that CYP epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage following cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac IR injury. Isolated C57BL/6J mouse hearts were perfused via Langendorff apparatus for 20 minutes to obtain baseline function followed by 30 minutes of global ischemia. Hearts were then treated with either vehicle, 19,20-EDP, SA-22, or SA-22 with the pan-sirtuin inhibitor nicotinamide (NAM), or the SIRT3-selective inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) at the start of 40 minutes reperfusion (N=5-8). We assessed IR injury-induced changes in recovery of myocardial function, using left ventricular developed pressure, systolic and diastolic pressure change. Tissues were assessed for ETC function, SIRT-1 and -3, optic atrophy type-1, and caspase-1. We also utilized H9c2 cells in an in vitro model of hypoxia/reoxygenation injury (N=3-6). Hearts perfused with SA-22 had significantly improved postischemic LVDP, systolic and diastolic recovery (64% of baseline), compared to vehicle control (15% of baseline). In addition, treatment with SA-22 led to better catalytic function observed in electron transport chain and SIRT enzymes. The protective action of SA-22 resulted in reduced activation of pyroptosis in both hearts or cells following injury. Interestingly, while NAM co-treatment worsened functional outcomes, cell survival and attenuated sirtuin activity, it failed to completely attenuate SA-22-induced protection against pyroptosis, possibly indicating EDPs exert cytoprotection through pleiotropic mechanisms. In short, these data demonstrate the potential of our novel synthetic 19,20-EDP analog, SA-22, against IR/HR injury and justifies further development of therapeutic agents based upon 19,20-EDP.

5 April 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ZZZhiheng Zhang
Zhiheng Zhang
HAHaruna Aoki
Haruna Aoki
KUKeitaro Umezawa
Keitaro Umezawa
JKJoshua Walter Kranrod
Joshua Walter Kranrod
NMNatsumi Miyazaki
Natsumi Miyazaki
SAShigeki Aoki
Shigeki Aoki
Although increased aerobic glycolysis is common in various cancers, pancreatic ductal adenocarcinoma (PDAC) cells can survive a state of glycolysis suppression. We aimed to identify potential therapeutic targets in glycolysis-suppressed PDAC cells. By screening anticancer metabolic compounds, we identified SP-2509, an inhibitor of lysine-specific histone demethylase 1A (LSD1), which dramatically decreased the growth of PDAC PANC-1 cells and showed an anti-tumoral effect in tumor-bearing mice. The growth of glycolysis-suppressed PANC-1 cells was also inhibited by another LSD1 inhibitor, OG-L002. Similarly, the other two PDAC cells (PK-1 and KLM-1) with suppressed glycolysis exhibited anticancer effects against SP-2509. However, the anticancer effects on PDAC cells were unrelated to LSD1. To investigate how PDAC cells survive in a glycolysis-suppressed condition, we conducted proteomic analyses. These results combined with our previous findings suggested that glucose-starvation causes PDAC cells to enhance mitochondrial oxidative phosphorylation. In particular, mitochondrial fatty acid metabolism was identified as a key factor contributing to the survival of PDAC cells under glycolysis suppression. We further demonstrated that SP-2509 and OG-L002 disturbed fatty acid metabolism and induced lipid droplet accumulation through the impairment of lipophagy, but not bulk autophagy. These findings indicate a significant potential association of lipophagy and anticancer effects in glycolysis-suppressed PDAC cells, offering ideas for new therapeutic strategies for PDAC by dual inhibition of glycolysis and fatty acids metabolism.

15 May 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JKJoshua Walter Kranrod
Joshua Walter Kranrod
AKAnne Konkel
Anne Konkel
RVRobert Valencia
Robert Valencia
ADAhmed M. Darwesh
Ahmed M. Darwesh
RFRobert Fischer
Robert Fischer
JSJohn M Seubert
John M Seubert
OMT-28 is a metabolically robust small molecule developed to mimic the structure and function of omega-3 epoxyeicosanoids. However, it remained unknown to what extent OMT-28 also shares the cardioprotective and anti-inflammatory properties of its natural counterparts. To address this question, we analyzed the ability of OMT-28 to ameliorate hypoxia/reoxygenation (HR)-injury and lipopolysaccharide (LPS)-induced endotoxemia in cultured cardiomyocytes. Moreover, we investigated the potential of OMT-28 to limit functional damage and inflammasome activation in isolated perfused mouse hearts subjected to ischemia/reperfusion (IR) injury. In the HR model, OMT-28 (1 μM) treatment largely preserved cell viability (about 75 versus 40% with the vehicle) and mitochondrial function as indicated by the maintenance of NAD+/NADH-, ADP/ATP-, and respiratory control ratios. Moreover, OMT-28 blocked the HR-induced production of mitochondrial reactive oxygen species. Pharmacological inhibition experiments suggested that Gαi, PI3K, PPARα, and Sirt1 are essential components of the OMT-28-mediated pro-survival pathway. Counteracting inflammatory injury of cardiomyocytes, OMT-28 (1 μM) reduced LPS-induced increases in TNFα protein (by about 85% versus vehicle) and NF-κB DNA binding (by about 70% versus vehicle). In the ex vivo model, OMT-28 improved post-IR myocardial function recovery to reach about 40% of the baseline value compared to less than 20% with the vehicle. Furthermore, OMT-28 (1 μM) limited IR-induced NLRP3 inflammasome activation similarly to a direct NLRP3 inhibitor (MCC950). Overall, this study demonstrates that OMT-28 possesses potent cardio-protective and anti-inflammatory properties supporting the hypothesis that extending the bioavailability of omega-3 epoxyeicosanoids may improve their prospects as therapeutic agents.